Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Ellen G. Driever"'
Autor:
Ellen G. Driever, Marta Magaz, Jelle Adelmeijer, Fanny Turon, Anna Baiges, Pol Olivas, Valeria Pérez‐Campuzano, Virginia Hernandez‐Gea, Annabel Blasi, Juan‐Carlos Garcia‐Pagan, Ton Lisman
Publikováno v:
Journal of Thrombosis and Haemostasis, 20(9), 2075-2082. Wiley
Background A hypercoagulable state is not associated with development of portal vein thrombosis in cirrhosis, as we previously demonstrated. However, some groups demonstrated elevated levels of inflammatory markers and activation of hemostasis in the
Autor:
Ellen G. Driever, Julie Brogaard Larsen, Sarah Bos, William Bernal, Anne-Mette Hvas, Ton Lisman
Publikováno v:
Research and practice in thrombosis and haemostasis, 7(1):100043. Wiley
Background: A plasma-based clot lysis time (CLT) assay is an established research test to assess plasma fibrinolytic potential, with application in hyperfibrinolytic or hypofibrinolytic conditions. Interprotocol variations make comparisons between la
Autor:
William M. Lee, Jingwen Zhang, Ellen G. Driever, Jelle Adelmeijer, Valerie Durkalski, R. Todd Stravitz, Ton Lisman
Publikováno v:
Hepatology, 73(5), 1882-1891. Wiley
Hepatology (Baltimore, Md.)
Hepatology (Baltimore, Md.)
Background and Aims Recent studies of acute liver failure (ALF) in man and animals have suggested that rebalanced hemostasis occurs, with distinct hypercoagulable features clinically evidenced by a low risk of bleeding. Rodent models have shown a lin
Publikováno v:
Journal of Thrombosis and Haemostasis. 21:188-189
Autor:
Ellen G. Driever, Ton Lisman
Publikováno v:
Seminars in thrombosis and hemostasis, 48(05), 596-606. THIEME MEDICAL PUBL INC
Patients with liver diseases are in a rebalanced state of hemostasis, due to simultaneous decline in pro- and anticoagulant factors. This balance seems to remain even in the sickest patients, but is less stable and might destabilize when patients dev
Autor:
Jaume Bosch, Genís Campreciós, Pol Olivas, Fabian Betancourt-Sanchez, Annalisa Berzigotti, Concepció Brú, Juan Carlos Reverter, Ellen G. Driever, Valeria Perez-Campuzano, Lara Orts, Anna Baiges, Eira Cerda, I. Núñez, Enric Reverter, Ángeles García-Criado, Juan Carlos García-Pagán, Annabel Blasi, Fanny Turon, Virginia Hernández-Gea, Rosa Gilabert, Ton Lisman, Roger Borràs, Susana Seijo, Marta Magaz
Publikováno v:
Journal of Hepatology, 75(6), 1367-1376. ELSEVIER SCIENCE BV
BACKGROUND & AIMS Portal vein thrombosis (PVT) is a relatively frequent event in patients with cirrhosis. While different risk factors for PVT have been reported, such as decreased portal blood flow velocity (PBFV) and parameters related with severit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f97b3aec021e691dbe36acf75019067a
https://research.rug.nl/en/publications/c9b8116b-92ab-4a00-baa8-ea490d901249
https://research.rug.nl/en/publications/c9b8116b-92ab-4a00-baa8-ea490d901249
Autor:
Robert J. Porte, Marius C. van den Heuvel, John W. Weisel, Ellen G. Driever, Stephen L. Gregory, Anabel Blasi, Jelle Adelmeijer, Robbert J. de Haas, Chandrasekaran Nagasami, Ton Lisman, Constantino Fondevila, William Bernal, Pauline Kane, Fien A. von Meijenfeldt, Yoh Zen, Nigel Heaton
Publikováno v:
Hepatology, 75(4), 898-911. Wiley
BACKGROUND AND AIM: Portal vein thrombosis (PVT) is a common complication of cirrhosis. The exact pathophysiology remains largely unknown, and treatment with anticoagulants does not lead to recanalization of the portal vein in all patients. A better